US panel warns of China’s biotech rise, fuelling push to curb ties as Chinese firms unfazed
Fresh warnings from a US congressional advisory body about the rapid rise of China’s biopharmaceutical sector are fuelling Washington’s push to curb cross-border ties, analysts said, though China’s industry appears largely unfazed. China was gaining a “competitive advantage” in biopharmaceuticals, and Western firms were increasingly paying large upfront fees to license Chinese drugs thanks to the…
We haven't written up this one. SCMP Business has the full story — the link below goes straight to it.